EPO Patent Bulletin: Immune Stimulating Antibodies Against IL-2 Fusion Proteins
Summary
The European Patent Office has published patent application EP3402819A1 concerning immune-stimulating humanized monoclonal antibodies against human interleukin-2 and fusion proteins thereof. The patent application was published on March 11, 2026, by applicant Universität Zürich.
What changed
This document is a publication of a European patent application (EP3402819A1) from Universität Zürich, detailing "IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF." The publication date is March 11, 2026.
This is a patent publication, not a regulatory rule or guidance. It does not impose new compliance obligations or deadlines on regulated entities. Legal professionals and researchers in the pharmaceutical and biotechnology sectors may find this patent application of interest for intellectual property and research and development purposes.
Source document (simplified)
IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
Publication EP3402819A1 Kind: A1 Mar 11, 2026
Applicants
Universität Zürich
Inventors
ARENAS-RAMIREZ, Natalia, BEUVINK, Iwan, BOYMAN, Onur, BRANNETTI, Barbara, KATOPODIS, Andreas, POPP, Simone, REGNIER, Catherine, ZOU, Chao
IPC Classifications
C07K 16/24 20060101AFI20170809BHEP A61K 38/20 20060101ALI20170809BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.